Please login to the form below

Not currently logged in
Email:
Password:

Paul Blake joins Oxford BioMedica

He will lead the development of pipeline of gene and cell therapies
paul blake oxford biomedica

Oxford BioMedica has named Dr Paul Blake as chief development officer.

Dr Blake, who is already a board member at the UK-based gene therapy specialist, will assume his new role on September 1. He will head the clinical development of the company's pipeline of gene and cell therapies.

Prior to taking the position at Oxford BioMedicia Dr Blake was senior VP and chief medical officer of Canada-based biopharma AEterna Zentaris- a position he held from 2006 to 2014.

His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.

John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”

27th August 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics